

## Format for ANSWERING REVIEWERS



April 16, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 17771-review.doc).

**Title:** Eribulin for heavily pre-treated metastatic breast cancer patients

**Author:** Antonia Digklia, Ioannis A Voutsadakis

**Name of Journal:** *World Journal of Experimental Medicine*

**ESPS Manuscript NO:** 17771

The manuscript has been improved according to the suggestions of reviewers:

Specifically:

- More extensive legends have been added in the figures and tables to make them more easy to read. The legends of the figures are situated in the end of the manuscript.
- ER has been spelled out as Estrogen Receptor. As per reviewer's remark we have changed PR to PgR when meaning Progesterone receptor while maintaining PR when meaning Partial Response.
- We believe that the 1<sup>st</sup> paragraph of results refers really to results data and thus we have chosen to maintain it in the results section instead of moving it to methods as one of the reviewers suggested.

Thank you for your consideration.

Sincerely,

Ioannis A. Voutsadakis, M.D., Ph.D.

Division of Med. Oncology, Dept. of Medicine

Sault Area Hospital, Sault Ste Marie, ON, Canada and

Division of Clinical Sciences

Northern Ontario School of Medicine

Editorial Board Member # 00181208